CN103172707B - Diagnosis marker Talin 1 segment for human immunodeficiency virus infection and application thereof - Google Patents
Diagnosis marker Talin 1 segment for human immunodeficiency virus infection and application thereof Download PDFInfo
- Publication number
- CN103172707B CN103172707B CN201110439824.5A CN201110439824A CN103172707B CN 103172707 B CN103172707 B CN 103172707B CN 201110439824 A CN201110439824 A CN 201110439824A CN 103172707 B CN103172707 B CN 103172707B
- Authority
- CN
- China
- Prior art keywords
- talin
- fragment
- diagnosis
- seq
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the field of biological medicine and relates to a diagnosis marker for human immunodeficiency virus infection. The invention initially provides a Talin-1 segment which can serve as a diagnosis marker for human immunodeficiency virus infection and a kit thereof. The Talin 1 segment is shown in SEQ ID NO 1 or SEQ ID NO 2. The invention also provides a corresponding kit and an application thereof. When the diagnosis marker or the kit is used for screening human immunodeficiency virus infection sufferers, a method is simple and easy to understand, operation is easy, cost is low, a diagnosis result can be provided more quickly, an infection sufferer can be helped to know pathogenic condition as early as possible, and a therapeutic schedule can be planned as early as possible and the pathogenic condition can be controlled as early as possible; and the diagnosis marker and the kit are especially applicable to detection on samples with low human immunodeficiency viral load. The diagnosis marker provided by the invention can be combined with other diagnosis methods or diagnosis markers, so that accuracy rate and sensibility of diagnosis are further increased.
Description
Technical field
The invention belongs to biomedicine field, relate to a kind of AIDS viral infection diagnostic flag.In particular to a kind of AIDS diagnosis mark and test kit thereof taking Talin 1 fragment as core.The present invention also provides using method and the application of corresponding reagent box.
Background technology
Acquired immune deficiency syndrome (AIDS), i.e. acquired immune deficiency syndrome (AIDS) (translating again: acquired immunity defect syndrome), the transliteration of english abbreviation AIDS (Acquired Immune Deficiency Syndrome).Be divided into amphitypy: HIV-1 type and HIV-2 type are that human injection has infected the transmissible disease that " human immunodeficiency virus " (HIV-human immunodeficiency virus) (claiming again hiv virus) causes.Acquired immune deficiency syndrome (AIDS) is called as " pestilence in century after history ", is also referred to as " super cancer " and " century killer ".
Acquired immune deficiency syndrome (AIDS), is kind of a zoonosis, causes by infecting " HIV " virus.HIV is a kind of virus that can attack human immune system.It is using most important T4 Lymphoid tissue in human immune system as target of attack, and considerable damage T4 Lymphoid tissue, produces high fatefulue interior exhaustion.This virus infects throughout one's life in region, destroys people's immunologic balance, makes human body become the carrier of various diseases.
Patients infected hiv is counted from initial infection, be through the several years, even reach 10 years or just can develop into AIDS patients after longer latent period.AIDS patients there will be multi-infection because resistivity extreme declines, as zoster, Fungi Infection of Oral, pulmonary tuberculosis, enteritis, pneumonia, encephalitis that specific disease pathogenic microorganism causes, candidiasis, the severe infections that the multiple pathogens such as lung sac worm cause etc., usually there is malignant tumour in the later stage, until consume because of long-term, and cachexia and death.
Acquired immune deficiency syndrome (AIDS) is seriously threatening the mankind's existence, has caused the great attention of the World Health Organization and national governments.Acquired immune deficiency syndrome (AIDS) propagation is worldwide more and swifter and more violent, and the mankind's health and social development in serious threat, has become the fourth-largest killer who threatens health of people.UNAIDS announced on May 30th, 2006 since confirming acquired immune deficiency syndrome (AIDS) first in June, 1981, and between 25 years, whole world accumulative total has 6,500 ten thousand people's aids infection poison, wherein 2,500,000 people's death.
Although the numerous medical research personnel in the whole world have paid huge effort, not yet develop so far the specific medicament of radical cure acquired immune deficiency syndrome (AIDS), not can be used for the effective vaccine of prevention yet.At present, this case fatality rate is almost listed in Class B Notifiable disease by China up to 100% " super cancer ", and is listed in one of border monitoring of hygiene transmissible disease.So we call it " super incurable disease ".
Hiv virus belongs to RNA viruses, and because RNA is strand, it is stable like that not as DNA double chain, so the mutation frequency of hiv virus is high, giving develops vaccine brings huge difficulty.And hiv virus is retrovirus, so-called retrovirus is that it is being invaded after host cell, taking oneself single stranded RNA as template, according to base complementrity pair principle, under the effect of reversed transcriptive enzyme, synthetic cDNA, new synthetic cDNA inserts in host's core DNA, copies, transcribes, translates and reach amplification object virus with host DNA.
The methods for the treatment of of acquired immune deficiency syndrome (AIDS) has: nutrition treatment, stem cell bone marrow transplantation, fruit treatment, anti-HIV agent, immunoregulation druge, operative treatment, vaccinetherapy etc.But, there is no at present the effective vaccine preventing AIDS.
Acquired immune deficiency syndrome (AIDS) detection principle, refers to that adopting laboratory method to carry out hiv virus, antibody of AIDS virus and related immune index to blood of human body, other body fluid, histoorgan, blood derivatives etc. detects.
The diagnosis basis of acquired immune deficiency syndrome (AIDS), mainly taking virus antibody positive as main, is aided with following any one person, can be experiment and makes a definite diagnosis AIDS patients.
(1) at no distant date (3-6 month) loses weight more than 10%, and persistent fever reaches 38 DEG C more than one month.
(2) at no distant date (3-6 month) loses weight more than 10%, continues diarrhoea (reach 3-5 every day) more than one month.
(3) pneumocystis carinii pneumonia (PCR).
(4) kaposi's sarcoma KS.
(5) significantly mould or other conditions are pathogenic infects.
The latent period average out to 8 year to 9 year of hiv virus in human body, is developing into before AIDS patients, and patient's appearance looks normally, and they can be without any a lot of years of symptom ground live and work.HIV itself can't cause any disease, but after immunity system is destroyed by HIV, and human body, because resistivity is too low, is lost and copied the chance of immunocyte, and the disease that infects other causes various diseases multiplicity of infection and death.How the patients infected hiv of making a definite diagnosis of morning is one of important topic of this area.
Summary of the invention
The diagnostic flag that the problem to be solved in the present invention provides a kind of hiv virus carrying capacity to detect, assisted diagnosis patients infected hiv, especially for latent period, patient that virus load is lower.
Another problem that the present invention will solve provides a kind of diagnostic kit of AIDS viral infection.
The present invention is based on inventive concept below: research shows, the lower fragment of molecular weight of talin 1 protein raises in HIV the infected, and object fragment is positioned at C end, illustrates that the fragmentation of Talin-1 and the infection of HIV are closely related.By protein group in detection HIV the infected and healthy volunteer's mononuclearcell, find that the Talin-1 fragment expression amount of about 38Kda size in HIV the infected's body increases significantly, and the expression amount of this Talin-1 fragment and virus load negative correlation.This negative correlation prompting, the Talin-1 of newly-generated fragmentation can be used as the clinical monitoring index at a novel HIV (human immunodeficiency virus) infection initial stage.Further complete on this basis the present invention.
The invention provides a kind of diagnostic flag of AIDS viral infection, described diagnostic flag is Talin 1 fragment; Described Talin 1 fragment is as shown in SEQ ID NO 1 or SEQ ID NO 2.
Described diagnostic flag can be made up of the polypeptide shown in the polypeptide shown in SEQ ID NO 1 and SEQ ID NO 2.These two polypeptide chains independently unit of respectively doing for oneself, the independently polypeptide chain of both can respectively having done for oneself, also can be subordinated to same polypeptide chain, is connected in sequentially on same polypeptide chain one of midfeather or several amino-acid residues.
Described diagnostic flag can be also the DNA encoding sequence of Talin 1 fragment; Described Talin 1 fragment is as shown in SEQ ID NO 1 or SEQ ID NO 2.
Described diagnostic flag can be made up of the DNA encoding sequence of polypeptide shown in the DNA encoding sequence of polypeptide shown in SEQ ID NO 1 and SEQ ID NO 2.These two DNA chains independently unit of respectively doing for oneself, both can be separately in DNA chain independently, also can be subordinated to same DNA chain, be connected in sequentially on same polypeptide chain one of both midfeather or several Nucleotide.
The present invention also provides the application of above-mentioned diagnostic flag, in brief, sample and above-mentioned any one diagnostic flag is contrasted, and detects in sample whether contain above-mentioned diagnostic flag.
Preferably, can further detect the quantity that contains described diagnostic flag in sample.
In one embodiment of the invention, the method that detects Talin 1 fragment is as follows: collect peripheral blood, separation and Culture peripheral blood mononuclear cell, gets protein sample, utilizes immunoblotting assay method to detect the wherein content of Talin 1 fragment.
The invention provides a kind of test kit of diagnosis of aids, this test kit contains above-mentioned any one diagnostic flag.
Described test kit also contains molecular weight marker reagent.In addition, can also contain damping fluid, the albumen of small molecules amount or nucleic acid marking, internal reference reagent or specification sheets, etc.
An aspect of of the present present invention, provides a kind of Talin 1 fragment polypeptide of separation, and it comprises: polypeptide or its conservative property variation polypeptide or its active fragments or its reactive derivative with the aminoacid sequence of SEQ ID NO:1h or 2.Preferably, this polypeptide is the polypeptide with the aminoacid sequence of SEQ ID NO:1 or 2.
Another aspect of the present invention, provides a kind of polynucleotide encoding sequence of Talin 1 fragment polypeptide of separation, and it comprises: polynucleotide encoding sequence and the degenerate sequence thereof with the aminoacid sequence of SEQ ID NO:1 or 2.This degenerate sequence refers to, the sequence that has one or more codons to be encoded to produce after the degenerate codon of same amino acid replaces.Due to the degeneracy of codon, so be low to moderate with the nucleotide coding sequence homology of SEQ ID NO:1 or 2 aminoacid sequence that approximately 70% degenerate sequence also can be encoded out described in SEQ ID NO:1 or 2.
In practice, can be according to this polypeptide of aminoacid sequence synthetic of Talin 1 fragment polypeptide.Also the encoding sequence of Talin 1 fragment polypeptide of the present invention can be connected with carrier, for amplification or expression Talin 1 fragment polypeptide.
In another aspect of this invention, provide a kind of generation to have the method for Talin 1 fragment polypeptide, the method comprises:
(a) nucleotide sequence of coding Talin 1 fragment polypeptide is operationally connected in to expression regulation sequence, forms Talin 1 fragment expression of polypeptides carrier, described Talin 1 fragment polypeptide is identical with the aminoacid sequence of SEQ ID NO:1 or 2;
(b) expression vector in step (a) is proceeded to host cell, form the reconstitution cell of Talin 1 fragment polypeptide;
(c) be applicable to expressing under the condition of Talin 1 fragment polypeptide the reconstitution cell in culturing step (b);
(d) isolate the polypeptide with Talin 1 fragment polypeptide active.
In another aspect of this invention, provide a kind of method that detects AIDS viral infection, the method comprises: collect person's to be detected blood sample or body fluid, detect the wherein content of Talin 1 fragment polypeptide.
In one embodiment, provide sample to be tested whether to have the method for Talin 1 fragment polypeptide, it comprises step: testing sample is contacted with the specific antibody of anti-Talin 1 fragment polypeptide; Detect and whether formed immunocomplex, form immunocomplex and just represent that this sample to be tested contains Talin 1 fragment polypeptide.
In practice, can also be by detecting the nucleic acid coding sequence that whether has Talin 1 polypeptide in sample, it comprises step: with the Auele Specific Primer of Talin 1 fragment polypeptid coding sequence, with the increase mRNA of this sample of RT-PCR method; Detect and whether have the Talin of expectation 1 fragment polypeptide amplified production, exist amplified production just to represent that HIV (human immunodeficiency virus) infection has occurred this sample.
In another embodiment, the method is the transcript that whether has Talin 1 fragment polypeptide in sample by detecting, and it comprises step: with the specific probe of Talin 1 fragment polypeptide-nucleic acid encoding sequence, with the cDNA sample hybridization of this sample; Detect and whether have hybridization product, exist hybridization product just to represent that HIV (human immunodeficiency virus) infection has occurred this sample.
In another aspect of this invention, a kind of test kit that detects AIDS viral infection is also provided, it contains: the primer pair of (1) specific amplification Talin 1 fragment nucleic acid coding sequence, the required reagent of reverse transcription mRNA that (2) are optional.The another kind of test kit that detects AIDS viral infection, contains the specific antibody for Talin 1 fragment polypeptide.The another kind of test kit that detects AIDS viral infection, containing can be specifically and the probe of the mRNA hybridization of Talin 1 fragment polypeptide.
In the present invention, can select various carrier known in the art, as commercially available carrier.Such as, select commercially available carrier, then the nucleotide sequence of code book invention polypeptide is operationally connected in to expression regulation sequence, can form protein expression vector.
As used herein, " being operationally connected in " refers to so a kind of situation, and some part of linear DNA sequence can affect the activity of same other parts of linear DNA sequence.For example, if signal peptide DNA as precursor expression and participate in the secretion of polypeptide, signal peptide (secretion leader sequence) DNA is operationally connected in polypeptid DNA so; If transcribing of promotor control sequence, it is to be operationally connected in encoding sequence so; If when ribosome bind site is placed in the position that can make its translation, it is to be operationally connected in encoding sequence so.Generally, " being operationally connected in " means adjoining, means in reading frame adjacent for secretion leader sequence.
In the present invention, term " host cell " comprises prokaryotic cell prokaryocyte and eukaryotic cell.The example of conventional prokaryotic host cell comprises intestinal bacteria, Bacillus subtilus etc.Conventional eukaryotic host cell comprises yeast cell, insect cell and mammalian cell.Preferably, this host cell is eukaryotic cell, as Chinese hamster ovary celI, COS cell etc.
On the other hand, the present invention also comprises that Talin 1 fragment polypeptide is had to specific polyclonal antibody and monoclonal antibody, especially monoclonal antibody.Here, " specificity " refers to that antibody capable is incorporated into Talin 1 fragment polypeptide.Preferably, refer to that those can be combined with Talin 1 fragment polypeptide but nonrecognition and be incorporated into the antibody of other irrelevant antigen molecule.In the present invention antibody comprise those can in conjunction with and suppress the molecule of Talin 1 fragment polypeptide, also comprise that those do not affect the antibody of Talin 1 fragment polypeptide function.The present invention also comprise those can with modify or the antibody of being combined without the Talin 1 fragment polypeptide of modified forms.
The present invention not only comprises complete mono-clonal or polyclonal antibody, but also comprises having immunocompetent antibody fragment, as Fab ' or (Fab)
2fragment; Heavy chain of antibody; Light chain of antibody; Genetically engineered scFv molecule (people such as Ladner, U.S. Patent No. 4,946,778); Or chimeric antibody, as there is murine antibody binding specificity but still retain the antibody from people's antibody moiety.
Antibody of the present invention can be prepared by the known various technology of those skilled in that art.For example, the Talin 1 fragment polypeptide of purifying or its have antigenic fragment, can be applied to the generation of animal with induction polyclonal antibody.Similarly, expression Talin 1 fragment polypeptide or its cell with antigenic fragment can be used to immune animal and produce antibody.Antibody of the present invention can be also monoclonal antibody.This type of monoclonal antibody can utilize hybridoma technology prepare (see the people such as Kohler,
nature256; 495,1975; The people such as Kohler,
eur.J.Immunol.6:511,1976; The people such as Kohler,
eur.J.Immunol.6:292,1976; The people such as Hammerling,
in Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981).Antibody of the present invention comprises the antibody that can block Talin 1 fragment polypeptide function and the antibody that does not affect Talin 1 fragment polypeptide function.Each antibody-like of the present invention can utilize fragment or the functional zone of Talin 1 fragment polypeptide, obtains by routine immunization technology.These fragments or functional zone can utilize recombination method preparation or utilize Peptide synthesizer synthetic.The antibody of being combined with the unmodified form of Talin 1 fragment polypeptide can for example, carry out immune animal and produce by the gene product of producing in prokaryotic cell prokaryocyte (E.Coli); The antibody (as the albumen of glycosylation or phosphorylation or polypeptide) of being combined with posttranslational modification form, can for example, carry out immune animal and obtain by the gene product producing in eukaryotic cell (yeast or insect cell).
The present invention provides the Talin-1 fragment and the test kit thereof that can be used as AIDS viral infection diagnostic flag first.Use this diagnostic flag or test kit screening AIDS viral infection patient, method is simple, easy to operate, with low cost, easy-to-understand, and diagnostic result can be provided faster, helps infected patient to understand as early as possible the state of an illness, formulates treatment plan, controls the state of an illness.Be particularly suited for detecting the sample that hiv virus virus load is low.Diagnostic flag of the present invention can be combined use with other diagnostic methods or diagnostic flag, further to improve accuracy rate and the susceptibility of diagnosis.
Brief description of the drawings
Fig. 1 is the electrophoresis partial enlarged drawing of Talin-1 fragmentation in HIV patient.Wherein, N1, N2, and N3 represents to repeat for three times of human normal plasma experiment, and H1, H2 and H3 represent the AIDS patient's sample without HAART treatment.TLN1 base Talin-1 of the present invention in figure.
Fig. 2 is the 38KDa frag info of Mass Spectrometric Identification talin-1.
Fig. 3 is the expression of the 38KDa fragment of immunoblotting assay talin 1 in 11 healthy volunteers and 12 AIDS patients' PBMC.
Fig. 4 is near amount and the virus load negative correlation figure of Talin-1 fragment 38KDa.
Fig. 5 is MRM detection by quantitative Talin-1C end peptide section.Wherein 1-4 is low virus load sample, and 5-7 is normal specimen, and 8-10 is high virus load sample.
Fig. 6 is that after HIV pseudovirus infection TZM-bl cell, fragmentation and the apoptosis in corresponding stage of Talin-1 detects.
Fig. 7 is that the apoptosis that virus load is relevant detects.The immunoblot experiment that cell model in 3.2 is carried out conventionally to caspase, result shows: in whole pseudovirus stimulating course, obvious apoptosis does not all occur cell.
Embodiment
Embodiment 12DE-MS finds first Talin-1 fragmentation in HIV the infected
Adopt the technological line of 2DE-MS to detect without protein group in HIV the infected of HAART treatment and healthy volunteer's mononuclearcell, find talin 1, vinculin, the lower fragment of molecular weight of the protein such as filamin A raises (seeing Fig. 1) in HIV the infected, and object fragment is positioned at C end.TLN1 base Talin-1 of the present invention in figure.
This results suggest: in the HIV the infected who does not treat through HAART, Talin-1, at its C end, fragmentation has occurred, and has obtained good checking in clinical sample.
The dependency of embodiment 2 information biology checking Talin 1 and interacting protein and HIV protein
Adopt STRING 8.0 softwares (http://string.embl.de) and HIV and the interactional database of host cell (http://www.ncbi.nlm.nih.gov/RefSeq/HIVInteractions.) to analyze the interaction of talin 1 with HIV protein and host cell proteins matter, find that talin 1 has participated in the pol of HIV and the network of vif gene regulating.This is consistent with the result of Fig. 1: the several protein in this network all have the fragment (seeing Fig. 1) of up-regulated in HIV the infected.Show: the fragmentation of Talin-1 is not independently fortuitous phenomena of one, but be positioned among a complicated interactive network.Therefore its fragmentation is very likely a kind of host in the face of HIV invade the active reaction of taking, thus the viral further infection of impact.
Embodiment 3 checks the relation of talin-1 fragment and HIV virus load in clinical samples
3.1.Western Blotting detects the relation of Talin-1 fragment and HIV virus load
Collect through HAART treatment after 6 months virus load lower than 50 or higher than 70 patient EDTA anticoagulated whole blood, separate PBMC, (g) loading of 50 μ is carried out immunoblot experiment by the primary antibodie of anti-talin-1 to equal protein matter.
Result shows: amount and the virus load negative correlation (Fig. 4) of near Talin-1 fragment 38KDa.
3.2MRM tests the fragment of quantitative talin 1
A. nonredundancy peptide section screening
According to the peptide section of Mass Spectrometric Identification, tentative prediction 38KDa fragment is the C-end fragment of talin 1.Then analyze and finally selected the unique peptide of VGAIPANALDDGQWSQGLISAAR (SEQ ID NO 1) and these two Talin-1 of LAQAAQSSVATITR (SEQ ID NO 2) as the foundation of Talin-1 being carried out to mass spectrum detection by quantitative.
B. the quantitative analysis of polypeptide
Adopt Dai Anna to rise liquid chromatography Ultra3000 series connection Brooker ion trap mass spectrometry HCT and carry out Talin-1MRM detection by quantitative.Get the aids patient PBMC sample of 4 HIV virus load < 50 aids patients, 3 Healthy Peoples and 3 HIV virus load > 50, extract total cellular proteins, measure after protein content, respectively get 50ug and carry out one dimension SDS-PAGE electrophoresis, after electrophoresis finishes, carry out coomassie brilliant blue staining.Cut the band of 38kDa, decolour dewatered freeze-dried after, carry out reductive alkylation with DTT and IAA, (0.02 μ g/ μ l) in every pipe, to add approximately 20 μ l pancreatin.37 DEG C of enzymolysis spend the night (16～18h).Enzyme is cut after peptide section extracts, and carries out MRM detection by quantitative by the Dai Anna upgrade liquid chromatogram Ultimate 3000 heavy body ion trap mass spectrometry (LC-MS/MS) of connecting.Peptide section sample first passes through C18 pre-column, and (flow velocity is 20 μ L/min for 300 μ m id x5mm, m) desalination of 5 μ, and moving phase is 2%ACN and 0.1%FA.Then with the flow velocity of 300nL/min through the reverse post of C-18 (75 μ m internal diameter x 15cm length, 3 μ m) separate, the gradient of chromatogram is 4-48%, the gradient time is 60min.The peptide section separating by C18 chromatographic column enters HCT mass spectrum and carries out real-time ionization analyzing and testing by receiving stream nozzle needle.Choose the detection by quantitative that Talin-1C end peptide section m/z770.8 (sequence is VGAIPANALDDGQWSQGLISAAR) and m/z 708.9 (sequence is LAQAAQSSVATITR) carry out MRM, corresponding daughter ion is respectively y4 (m/z 404.2) and y5 (m/z 561.3), when setting chromatogram gradient runs to 20-28min, mass spectrum MRM detects ion pair 770.8/404.2, and when 30.5-42min, MRM detects 708.9/561.3.
The results are shown in Figure 5.
Result shows, 4 samples of HIV virus load < 50 all can detect two Talin-1 peptide sections, in 3 normal specimen, only have 1 and Talin-1 peptide section can be detected, and in 3 samples of virus load > 50, also only have 1 sample two talin-1 peptide sections can be detected simultaneously.
This presentation of results Talin-1 fragmentation and virus load be negative correlation.
MRM shows in conjunction with Western Blotting result, and the fragmentation of Talin-1 and HIV virus load present strong negative correlation, for the invention provides strong evidence.Because if the fragmentation of Talin-1 is the degraded of skimble-skamble simple protein to be caused or promotes viral propagation in host, so, its fragmentation should be proportionate with virus load.
And be just this negative correlation hint, the Talin-1 of newly-generated fragmentation is likely to possess the functional peptide fragment that suppresses HIV effect, can be used as the clinical monitoring index at a novel HIV (human immunodeficiency virus) infection initial stage.
Embodiment 4 verifies that in cell model the timing node of fragmentation occurs Talin-1
First in 293T cell, packaging obtains functional HIV pseudovirus, obtains after pseudovirus through titer determination, attacks malicious TZM-bl clone with active HIV pseudovirus, respectively after hatching altogether 0.5,1,2,4,8, within 12,24,48 and 72 hours, collect equivalent cell, cracking obtains total protein of cell, carries out immediately the Western Blotting of talin 1.Experimental result shows that the expression of 38KDa fragment starts to increase from 2h, within 2 to 48 hours, keeps substantially constant, and after 72 hours, expression amount reduces (Fig. 6) relatively.
The fragmentation of this results suggest: Talin1 may occur at poisoning intrusion cell stage.In addition, whole course of infection does not detect that apoptosis occurs, and shows that Talin-1 fragmentation is not due to apoptosis induction cuts.
Embodiment 5 Talin-1 fragmentations are not caused by apoptosis
Be by due to the no apoptosis causing due to virus infection in order to understand fragmentation, to the clinical sample of using in embodiment 3, carry out apoptosis degree detection, according in caspase 35 and the power of two western blot hybridization bands of 17KDa judge.
WB analyzes the relation of Caspase-3 cutting and HIV-1 carrying capacity, result shows, although at virus load during lower than 50 copy/ml, still the cutting of Caspase-3 can be detected, but in higher virus copy content sample, more Caspase-3 cutting can be detected, point out low Talin-1 fragmentation in high virus load sample be not due to the albumen that increasing apoptosis causes more extensively degrade cause (Fig. 7).
The immunoblot experiment that cell model in embodiment 4 is carried out conventionally to caspase, result shows: in whole pseudovirus stimulating course, obvious apoptosis (seeing Fig. 6) does not all occur cell.
Think between the fragmentation of Talin-1 and apoptosis, there is no obvious dependency according to above-mentioned experimental result.
SEQUENCE LISTING
<110> Shanghai Public Health Clinical Center
Diagnostic flag Talin 1 fragment and the application thereof of <120> AIDS viral infection
<130> 201191
<160> 2
<170> PatentIn version 3.1
<210> 1
<211> 23
<212> PRT
<213> synthetic
<400> 1
Val Gly Ala Ile Pro Ala Asn Ala Leu Asp Asp Gly Gln Trp Ser Gln
1 5 10 15
Gly Leu Ile Ser Ala Ala Arg
20
<210> 2
<211> 14
<212> PRT
<213> synthetic
<400> 2
Leu Ala Gln Ala Ala Gln Ser Ser Val Ala Thr Ile Thr Arg
1 5 10
Claims (6)
1. a diagnostic flag for AIDS viral infection, is characterized in that, described diagnostic flag is Talin 1 fragment; Described Talin 1 fragment is as shown in SEQ ID NO 1 or SEQ ID NO 2.
2. diagnostic flag as claimed in claim 1, is characterized in that, described diagnostic flag is made up of the polypeptide shown in the polypeptide shown in SEQ ID NO 1 and SEQ ID NO 2.
3. a diagnostic flag for AIDS viral infection, is characterized in that, described diagnostic flag is the DNA encoding sequence of Talin 1 fragment; Described Talin 1 fragment is as shown in SEQ ID NO 1 or SEQ ID NO 2.
4. diagnostic flag as claimed in claim 3, is characterized in that, described diagnostic flag is made up of the DNA encoding sequence of aminoacid sequence shown in the DNA encoding sequence of aminoacid sequence shown in SEQ IDNO 1 and SEQ ID NO 2.
5. a test kit for diagnosis of aids virus infection, is characterized in that, this test kit contains in claim 1-4 any one diagnostic flag.
6. test kit as claimed in claim 5, is characterized in that, described test kit also contains molecular weight marker reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110439824.5A CN103172707B (en) | 2011-12-23 | 2011-12-23 | Diagnosis marker Talin 1 segment for human immunodeficiency virus infection and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110439824.5A CN103172707B (en) | 2011-12-23 | 2011-12-23 | Diagnosis marker Talin 1 segment for human immunodeficiency virus infection and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103172707A CN103172707A (en) | 2013-06-26 |
| CN103172707B true CN103172707B (en) | 2014-09-03 |
Family
ID=48632955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110439824.5A Expired - Fee Related CN103172707B (en) | 2011-12-23 | 2011-12-23 | Diagnosis marker Talin 1 segment for human immunodeficiency virus infection and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103172707B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7097993B2 (en) * | 2003-06-25 | 2006-08-29 | Wisconsin Alumni Research Foundation | Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity |
| WO2009075883A2 (en) * | 2007-12-12 | 2009-06-18 | University Of Georgia Research Foundation, Inc. | Glycoprotein cancer biomarker |
| EP2105740A1 (en) * | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Biomarkers for monitoring or predicting the treatment of cancer |
| CN102174109A (en) * | 2011-01-21 | 2011-09-07 | 中华人民共和国吉林出入境检验检疫局 | Acquired immune deficiency syndrome virus and treponema pallidum fusion protein as well as preparation method and application thereof |
-
2011
- 2011-12-23 CN CN201110439824.5A patent/CN103172707B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103172707A (en) | 2013-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gu et al. | Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2 | |
| Wang et al. | Zika virus infection induces host inflammatory responses by facilitating NLRP3 inflammasome assembly and interleukin-1β secretion | |
| He et al. | NLRP3 inflammasome activation mediates Zika virus–associated inflammation | |
| Azad et al. | Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry | |
| Londono-Renteria et al. | A relevant in vitro human model for the study of Zika virus antibody-dependent enhancement | |
| CN105384803A (en) | Schistosoma japonicum katsurada recombinant protein SjSAPLP4 as well as encoding gene and application thereof | |
| Guenthoer et al. | Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection | |
| CN107531780A (en) | Anti- Rho GTPase conformation single domain antibody and application thereof | |
| Borca et al. | The Ep152R ORF of African swine fever virus strain Georgia encodes for an essential gene that interacts with host protein BAG6 | |
| Lim et al. | Development of a enterovirus diagnostic assay system for diagnosis of viral myocarditis in humans | |
| Gong et al. | COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte | |
| Chia et al. | Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor | |
| CN101768214B (en) | Human tumor marker-Tim17 polypeptide and application thereof | |
| CN101401807B (en) | Uses of selective JAK3 restrainer VI in antiviral mediated acute lung damnification | |
| CN105738624B (en) | A kind of indirect immunofluorescene assay method of Rift Valley fever virus IgG antibody | |
| CN103172707B (en) | Diagnosis marker Talin 1 segment for human immunodeficiency virus infection and application thereof | |
| Li et al. | A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD | |
| CN115290895B (en) | Application of methylation modification of 162 th lysine of human PD-L1 protein in prediction of malignant tumor immunotherapy sensitivity | |
| Wang et al. | LCP1 knockdown in monocyte-derived macrophages: mitigating ischemic brain injury and shaping immune cell signaling and metabolism | |
| CN105535975A (en) | Applications of vesicle-associated membrane protein 1 in prevention and treatment of enterovirus 71 infection | |
| Embury-Hyatt et al. | Generation and characterization of a monoclonal antibody against an African swine fever virus protein encoded by the A137R gene | |
| CN105311647A (en) | Application of Cofilin in preventing and treating Japanese encephalitis virus infection | |
| CN109503712B (en) | Monoclonal antibody ZKns2E11 and application thereof | |
| Yao et al. | Chikungunya virus glycoproteins transform macrophages into productive viral dissemination vessels | |
| CN105435245B (en) | Application of the calcium integrin Binding Protein 1 in prevention and treatment enterovirns type 71 infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140903 Termination date: 20161223 |